117 results on '"Mauriac L"'
Search Results
2. An EORTC phase I study of capecitabine (Xeloda®) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancer
3. Fulvestrant (Faslodex™) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials
4. The impact of loco-regional radiotherapy on the survival of breast cancer patients: Arbiter
5. 5016 POSTER DISCUSSION BIG 1-98 Update: Evaluating Letrozole and Tamoxifen Alone and in Sequence at 8 Years Median Follow-up for Postmenopausal Women With Steroid Hormone Receptor-Positive Breast Cancer
6. 5062 POSTER Rechallenge With Docetaxel After a First Response In Metastatlc Breast Cancer – a Significant Activity With Manageable Toxicity
7. Fulvestrant (Faslodex®) is effective in postmenopausal women with visceral metastases (VM) in advanced breast cancer (ABC)
8. ICI 182,780 (‘FASLODEX’) is at least as effective as anatrozole (Arimidex™) in post-menopausal women with advanced breast cancer progressing on prior endocrine treatment
9. Correlation of Immunohistochemistry (IHC) and gene microarray analysis of breast biopsies from a preoperative endocrine therapy trial
10. Cyclophosphamide (C) - Epirubicine (E) - Capecitabine (X) combination, CEX: A safe and active regimen in the treatment of locally advanced/inflammatory (LA/I) or large operable (LO) breast cancer (BC). An EORTC-IDBBC study
11. ICI 182,780 (Faslodex™) versus anastrozole (Arimidex™) for the treatment of advanced breast cancer in postmenopausal women — prospective combined analysis of two multicenter trials
12. Survival update of so14999 a large phase III trial of capecitabine/doxetaxel combination therapy vs docetaxel monotherapy in patients with locally advanced (LABC) or metastatic breast cancer (MBC)
13. Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women
14. Efficacy and safety of docetaxel (Taxotere™) in heavily pretreated advanced breast cancer patients
15. The added value of the combined evaluation of clinical efficacy, quality of life and cost-effectiveness in a randomized phase III study. Results of an EORTC — NCIC — SAKK neoadjuvant trial in patients with locally advanced breast cancer (LABC)
16. Neoadjuvant chemotherapy for breast cancer (BC): is doxorubicin-cyclophosphamide (AC) combination still a standard regimen?
17. New drugs in breast cancer
18. Predictive factors of response to neo-adjuvant chemotherapy by immunohistochemistry (IHC)
19. A new standard treatment for advanced premenopausal breast cancer: A meta-analysis of the Combined Hormonal Agent Trialists Group (CHAT)
20. Long term survival of patients treated with neoadjuvant chemotherapy for operable breast tumors: Results of a randomized trial with a 10 year-follow-up
21. EORTC-IDBBC (Investigational Drug Branch for Breast Cancer): Seven years of active European collaboration
22. EORTC 10941; Final results of a phase II study of liarozole fumarate in patients with metastatic breast cancer
23. EORTC 10968; Phase I study of CaelyxTM at a six week interval in patients with metastatic breast cancer
24. Obvious peritumoral emboli: an elusive prognostic factor reappraised. Multivariate analysis of 1320 node-negative breast cancers
25. Endometrial carcinoma (EC) in women with breast cancer (BC)
26. Short term vs lifelong adjuvant tamoxifen in early breast cancer (EBC): A randomized trial (TAM-01)
27. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer *
28. Vinorelbine/5-FU combination in metastatic breast cancer chemotherapy. A retrospective study of 63 cases
29. PP-4-9 Breast cancer and in vitro fertilization
30. PP-3-3 Is axillary node dissection (A.N.D.) useful for microinfiltrative breast carcinoma (MIBC)?
31. PP-7-12 Dose-finding study of weekly oral vinorelbine (VRL) in patients (PTS) with advanced breast cancer (ABC): preliminary results
32. PP-6-22 Breast Cancer Outcome after Pregnancy
33. PP-8-1 Combined estroyen suppression and receptor (ER) blockade by buserelin (LHRH-A) and tamoxifen (TAM) in premenopausal metastatic breast cancer: Preliminary results of a 3-arm randomized study (EORTC 10881)
34. PP-4-37 Standards, options and recommendations (sor) project from the FNCLCC: Non metastatic breast cancer
35. PP-7-2 Neoadjuvant chemotherapy by VEC regimen in breast cancer. preliminary results of a phase II trial
36. PP-6-3 The selection of patients with DCIS for a clinical randomised trial: Differences between large participating centres
37. PP-6-4 Prognostic Significance of Obvious Peritumoral Emboli in 2692 Primary Operable Breast Carcinoma
38. PP-8-29 Initial characteristics and outcome of infiltrating lobular carcinomas (ILC): A retrospective study about 737 patients
39. PP-8-2 First line tamoxifen for invasive hormonal sensitive non metastatic breast carcinomas in young postmenopausal patients
40. PP-2-29 Axillary dissection for breast cancer: Long-term functional results
41. PP-3-19 axil 95
42. Pamidronate infusions as single-agent therapy for bone metastases: A phase II trial in patients with breast cancer
43. 365 Randomized trial between selective aromatase inhibitor formestane (®lentaron) vs tamoxifen as first-line hormonal therapy in postmenopausal patients with advanced breast cancer: Confirmation of bioequivalence in survival
44. 1366 Nursing care for chronic painful outpatients
45. 347 Steroids do reduce the severity and delay the onset of docetaxel (DXT) induced fluid retention: Final results of a randomized trial of the EORTC investigational drug branch for breast cancer (IDBBC)
46. 669 Long term (>10 years) prognostic value of estrogen and progesterone receptors for operable breast cancer
47. A randomized, multicentre trial evaluating aredia in breast cancer patients with bone metastases
48. Preliminary results of a randomized trial comparing short vs prolonged chemotherapy in metastatic breast cancer
49. 669 Long term (10 years) prognostic value of estrogen and progesterone receptors for operable breast cancer
50. 669 Long term (> 10 years) prognostic value of estrogen and progesterone receptors for operable breast cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.